Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019 Aug;44(4):495-507. doi: 10.1111/jcpt.12830
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Smith VK, Mansfield CA, Klaiber HA. Terrorist threats, information disclosures, and consumer sovereignty. Information economics and policy. 2013 Dec;25(4):225-34.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Goyal RK, Rajan SS, Essien EJ, Sansgiry SS. Effectiveness of FDA's new over-the-counter acetaminophen label warning requirements in improving consumer risk perception of liver damage. J Clin Pharm Ther. 2012 Dec;37(6):681-5. doi: 10.1111/j.1365-2710.2012.01371.x.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.